Dupont Capital Management’s Jasper Therapeutics JSPR Stock Holding History

Dupont Capital Management’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-30,000	Closed	-$2.98M	–	1771
2021 Q2	$2.98M	Hold	30,000	–	–	0.07%	247
2021 Q1	$2.98M	Hold	30,000	–	–	0.07%	229
2020 Q4	$3M	Hold	30,000	–	–	0.06%	242
2020 Q3	$2.98M	Hold	30,000	–	–	0.07%	232
2020 Q2	$3.04M	Hold	30,000	–	–	0.07%	223
2020 Q1	$2.88M	Buy	+30,000	New	+$2.94M	0.07%	206

Other funds holding JSPR

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPARFS

Leverage Partners Absolute Return Fund SPC Cayman Islands Ky1-11111, Cayman Islands $54M AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Dupont Capital Management's JSPR Position: Q3 2021 in Review

Dupont Capital Management sold out of Jasper Therapeutics (JSPR) in Q3 2021, closing a stake of 30,000 shares — an estimated $2.98M sold.

Dupont Capital Management first reported a position in JSPR in Q1 2020 and held it in 6 quarters. The position peaked at $3.04M in Q2 2020. 10 funds tracked by Wall St. Rank hold JSPR as of Q3 2021.

Dupont Capital Management reported no remaining Jasper Therapeutics position as of Q3 2021 after selling out during the quarter.
Dupont Capital Management sold 30,000 Jasper Therapeutics shares in Q3 2021, an estimated $2.98M.
Dupont Capital Management first reported a position in Jasper Therapeutics in Q1 2020 and held it in 6 quarters.
Dupont Capital Management's Jasper Therapeutics position peaked at $3.04M in Q2 2020.
10 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2021.

Based on Dupont Capital Management's 13F filing for Q3 2021, filed 3 Nov 2021.